neutrophil lymphocyte ratio and platelet lymphocyte ratio
neutrophil lymphocyte ratio and platelet lymphocyte ratio: explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients
Study summary
To explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients.
Eligibility
Sex
ALL
Min age
18 Months
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* All cases with age ≥ 18 years from both sexes female and male, having end-stage renal disease (ESRD), who have been on hemodialysis for at least three months and divided to 4 groups according to the median of NLR and PLR
Exclusion Criteria:
* • Patients aged \< 18 years old.
* Patient with autoimmune disease.
* Patient with liver cirrhosis.
* Patients with immunodeficiency.
* Patients with malignancy.
Primary outcome measure(s)
Mortality — 6 months The primary outcome measures in the study "High Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Are Associated with Poor Survival in Patients with Hemodialysis" is :- All-cause mortality, encompassing death from any cause These is the endpoint used to evaluate the prognostic significance of NLR and PLR in hemodialysis patients.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.